Status:
TERMINATED
Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation
Lead Sponsor:
Peking University People's Hospital
Conditions:
Leukemia
Eligibility:
All Genders
15-65 years
Phase:
NA
Brief Summary
Hematopoietic stem cell transplantation (HSCT) is one of the best, and sometimes the only, option for the treatment of leukemia. However, relapse rate was still the key question to influence the overa...
Detailed Description
Standard risk patients over 15 years old(except Ph+ ALL, AML t(8;21) and T-ALL) undergone unmanipulated blood and marrow transplantation following day 60 post-transplantation were randomized into trea...
Eligibility Criteria
Inclusion
- Standard risk of Recipients (CR1 or CR 2 of AML/ALL before transplantation except Ph+ ALL and T-ALL) of allogeneic stem cell transplantation with myeloablative conditioning regimens
- Standard risk of Recipients: CR1 or CR 2 of AML/ALL before transplantation
- Ph+ ALL, AML with t(8;21) and T-ALL were excepted
- Patients were at least 60 days post-transplantation
- Bone marrow monitoring was still Complete Remission (CR) and minor residual disease (MRD) was negative
- 15 years of age or older
- No serious infection
Exclusion
- Exposure to any other clinical trials prior to enrollment
- Active malignant disease relapse
- Active, uncontrolled infection
- Inability to comply with IL-2 treatment regimen
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2015
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT01517347
Start Date
January 1 2012
End Date
August 1 2015
Last Update
October 24 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xiaosu Zhao
Beijing, Beijing Municipality, China, 100044